Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
The pooled prevalence of GERD in the Indian population is 15.6 %
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Subscribe To Our Newsletter & Stay Updated